NRSN (NeuroSense Therapeutics) NonCurrent Deferred Liabilities: $0.00 Mil (As of Dec. 2025)


NRSN NeuroSense Therapeutics Ltd NRSN
29 GF Score
Price $0.72
! 2 Warning Signs
View Full Analysis

What is NeuroSense Therapeutics NonCurrent Deferred Liabilities?

NeuroSense Therapeutics NRSN +0.42% 29 NonCurrent Deferred Liabilities is $0.00 Mil as of Dec. 2025. GuruFocus rates NRSN with a GF Score™ of 29/100. The stock has 2 warning signs investors should review.

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

NeuroSense Therapeutics's non-current deferred liabilities for the quarter that ended in Dec. 2025 was $0.00 Mil.

NeuroSense Therapeutics NonCurrent Deferred Liabilities Related Terms

NeuroSense Therapeutics NonCurrent Deferred Liabilities Historical Data

* Premium members only.

The historical data trend for NeuroSense Therapeutics's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NeuroSense Therapeutics NonCurrent Deferred Liabilities Chart

NeuroSense Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
NonCurrent Deferred Liabilities
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

NeuroSense Therapeutics Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
NRSN
29GF Score
NeuroSense Therapeutics Ltd NRSN
NonCurrent Deferred Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a NonCurrent Deferred Liabilities of $0.00 Mil mean?
NeuroSense Therapeutics (NRSN) has a NonCurrent Deferred Liabilities of $0.00 Mil as of Dec. 2025. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on NeuroSense Therapeutics and its competitors.
Is NeuroSense Therapeutics' NonCurrent Deferred Liabilities too high?
NeuroSense Therapeutics' current NonCurrent Deferred Liabilities is $0.00 Mil. Overall, NeuroSense Therapeutics has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does NeuroSense Therapeutics' NonCurrent Deferred Liabilities compare to SER and PVCT?
NeuroSense Therapeutics' NonCurrent Deferred Liabilities of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Liabilities for a Biotechnology company?
A good NonCurrent Deferred Liabilities depends on the Biotechnology industry context. However, NonCurrent Deferred Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Liabilities mean?
A high NonCurrent Deferred Liabilities can signal that a stock is expensive relative to its fundamentals. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on NeuroSense Therapeutics and its competitors. NeuroSense Therapeutics's current NonCurrent Deferred Liabilities is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NeuroSense Therapeutics stock overvalued right now?
NeuroSense Therapeutics (NRSN) has a current NonCurrent Deferred Liabilities of $0.00 Mil. The current NonCurrent Deferred Liabilities is $0.00 Mil. NeuroSense Therapeutics' overall GF Score™ is 29/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Liabilities calculated?
NonCurrent Deferred Liabilities is calculated from a company's financial statements. For NeuroSense Therapeutics (NRSN), the current NonCurrent Deferred Liabilities is $0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

NeuroSense Therapeutics Business Description

Other Exchanges H1Z:Germany
Address 11 HaMenofim Street, Building B, Herzliya, ISR, 4672562
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
29GF Score

Get the complete analysis for NRSN

NonCurrent Deferred Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.72
Price